Results 171 to 180 of about 4,861,792 (337)

Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults

Clinical Pharmacology in Drug Development, EarlyView.
Abstract AZD7442, a combination of extended half‐life monoclonal antibodies tixagevimab and cilgavimab, was shown to neutralize previously circulating SARS‐CoV‐2 variants. This study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD7442 in healthy Chinese adults. In this randomized, placebo‐controlled, Phase 1 study, AZD7442
Nanyang Li, Jing Zhang, Wenhong Zhang, Zhongyuan Xu, Xiangcao Yao, Anqi He, Shuyuan Liu, Xiaoyun Ge, Jinxi Liu, Yunfei Li, Cecil Chi‐Keung Chen, Huixia Zhang   +11 more
wiley   +1 more source

Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers. [PDF]

Int J Mol Sci
Chatzipieris FP, Mavromoustakou K, Matsoukas JM, Mavromoustakos T.   +3 more
europepmc   +1 more source

Angiotensin II

Springer Reference Medizin, 2019
Stephanie Carmon, Nikki Matos, Rebecca Burnside, P. Moreno, Franco, Devang Sanghavi, J. Peters, D. Buchnea   +7 more
semanticscholar   +1 more source

Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation. [PDF]

, 1979
Stephen L. Swartz, Gordon H. Williams, Norman K. Hollenberg, Thomas J. Moore, Robert G. Dluhy   +4 more
openalex   +1 more source

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
Overview of a multi‐omics based drug repurposing strategy. The systematic drug repurposing strategy included the following steps: (1) osteoporosis driver signaling networks were identified from multi‐omics data; (2) drug functional modules were obtained using a network fusion approach to integrate drug similarity information; (3) all drugs were ranked ...
Dan‐Yang Liu, Hui Shen, Jonathan Greenbaum, Qiao‐Rong Yi, Shuang Liang, Yue Zhang, Jia‐Chen Liu, Chuan Qiu, Lan‐Juan Zhao, Qing Tian, Kuan‐Jui Su, Zhe Luo, Li Wu, Xiang‐He Meng, Hong‐Mei Xiao, Yun Deng, Yang Li, Dragana Lovre, Vivian Fonseca, Fernando L. Sanchez, Li‐Jun Tan, Hong‐Wen Deng   +21 more
wiley   +1 more source

Vasoactive Agents in Burn Patients: Perspectives on Angiotensin-II. [PDF]

J Burn Care Res
Mueller SW, Tran NM, Betthauser KD, Buckley MS, Shupp J, Wiktor AJ, Hill DM.   +6 more
europepmc   +1 more source

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT‐ACS Emulation Using National Health Insurance Claims Data

Clinical Pharmacology &Therapeutics, EarlyView.
Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real‐world effectiveness and safety of reduced‐dose prasugrel in
Li‐Wen Huang, Yee‐Jen Wu, Fang‐Ju Lin, Chien‐Chih Wu, Hsin‐Yi Huang, Chi‐Chuan Wang, Xiaojuan Li   +6 more
wiley   +1 more source

Leptin Mediates High-Fat Diet Sensitization of Angiotensin II–Elicited Hypertension by Upregulating the Brain Renin–Angiotensin System and Inflammation

HYPERTENSION, 2016
B. Xue, Yang Yu, Zhongmin Zhang, F. Guo, T. Beltz, R. Thunhorst, R. Felder, A. Johnson   +7 more
semanticscholar   +1 more source

Peripheral vascular resistance and angiotensin II levels during pulsatile and no-pulsatile cardiopulmonary bypass. [PDF]

, 1979
Kenneth M. Taylor, W H Bain, Marie Russell, J J Brannan, Ian Morton   +4 more
openalex   +1 more source

Impact of Antihypertensive Treatment on Outcomes of Adjuvant Bevacizumab for Ovarian Cancer (IATRO), Results from a Nationwide Emulated Clinical Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Antiangiogenic therapy with bevacizumab improves outcomes in ovarian cancer but induces hypertension, leading to major adverse cardiovascular events (MACE). While calcium channel blockers (CCBs) and angiotensin‐converting enzyme inhibitors (ACEi) are recommended for managing bevacizumab‐associated hypertension, their impacts on cancer progression and ...
Floriane Jochum, Élise Dumas, Joe‐Elie Salem, Stéphane Ederhy, Anne‐Sophie Hamy, Lise Lecointre, Enora Laas, Fabien Reyal, Fabrice Lecuru, Cherif Akladios, Paul Gougis   +10 more
wiley   +1 more source